NASDAQ: STSSSharps Technology Inc Stock
$2.07-0.05 (-2.36%)
Updated Jan 30, 2026
STSS Price
$2.07
Fair Value Price
N/A
Market Cap
$58.43M
52 Week Low
$1.65
52 Week High
$211.20
P/E
0x
P/B
0.13x
P/S
517.87x
PEG
N/A
Dividend Yield
N/A
Revenue
$306.34k
Earnings
-$104.37M
Gross Margin
-718.7%
Operating Margin
-33,385.77%
Profit Margin
-34,070.1%
Debt to Equity
0.03
Operating Cash Flow
-$14M
Beta
0.65
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
STSS Overview
Sharps Technology Incorporated is a medical device company that manufactures and sells safety syringe products in the U.S. Its 'Sharps Provensa' offering is a smart safety syringe designed to eliminate potentially infectious accidental needlestick injuries Sharps Technology was incorporated in 2017 and is headquartered in Melville, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine STSS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
STSS
Ranked#40 of 45
Ranked#40 of 45
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $4.31 | A | |
| $8.26 | A | |
| $23.47 | A |
Be the first to know about important STSS news, forecast changes, insider trades & much more!
STSS News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how STSS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
STSS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
STSS is good value based on its book value relative to its share price (0.13x), compared to the US Medical Instruments & Supplies industry average (3.12x)
P/B vs Industry Valuation
STSS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more STSS due diligence checks available for Premium users.
Valuation
STSS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
200.91x
Market
43.06x
STSS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.13x
Industry
3.12x
STSS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
STSS's financial health
Profit margin
Revenue
$83.6k
Net Income
-$105.3M
Profit Margin
-125,963.6%
STSS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
STSS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$444.0M
Liabilities
$10.7M
Debt to equity
0.03
STSS's short-term assets ($39.66M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STSS's short-term assets ($39.66M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STSS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.4M
Investing
-$187.5M
Financing
$196.8M
STSS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
STSS vs Medical Stocks
Sharps Technology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.